29 September 2016

Ultrasound diagnostics and cancer treatment

Roselektronika is developing an ultrasound complex for the treatment of breast and thyroid tumors

Specialists of the Rostec State Corporation Roselektronika Holding, with the participation of the Ministry of Education and Science of the Russian Federation, are developing a multifunctional medical complex for ultrasound diagnostics and therapy of neoplasms of the mammary and thyroid glands. The development, called Strela, is in the stage of preparation of design and technological documentation.


The complex is built on the innovative technology of HIFU therapy (High Intensity Focused Ultrasound, focused ultrasound of high intensity), which is increasingly being used worldwide as an alternative to surgical intervention. In some cases, HIFU therapy is the only method of treatment that allows the patient to save his life. The effect is achieved by ultrasound penetration through soft tissues, causing localized warming (about 90 degrees C), which leads to irreversible damage to diseased cells, causes protein denaturation and coagulation necrosis. At the same time, the high temperature does not extend beyond the pathological focus. No side effects were also detected.

The Strela complex provides the creation of a volumetric zone of high-intensity ultrasound in the depth of the body tissue by focusing radiation and displaying the course of the procedure with formal indicators and ultrasound image in In-mode. Performs ablation of neoplasms with a depth of 0.5-2.5 cm and dimensions of no more than 2 cm in any dimension. At the same time, the duration of ablation of one tumor does not exceed 1 hour. The equipment provides for the possibility of a safe emergency shutdown at the initiative of the operator or patient.

Strela has no analogues on the Russian market and, according to the developers, will be 1.5 times cheaper than its closest competitor, the Echopulse complex of the French company Theraclion.

Fibroadenoma of the breast is the most common benign lesion, occurs in 10% of women. About 5% of people are affected by thyroid tumors.

The development was presented at the Biotechmed conference, which was held on September 26-27 in Gelendzhik (Krasnodar Territory) under the patronage of the Ministry of Industry and Trade and the Ministry of Health of the Russian Federation.

Portal "Eternal Youth" http://vechnayamolodost.ru  29.09.2016

Found a typo? Select it and press ctrl + enter Print version